The Testosterone Trial in Older Men

This study is ongoing, but not recruiting participants.
National Institute on Aging (NIA)
National Institute of Neurological Disorders and Stroke (NINDS)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
University of Pennsylvania Identifier:
First received: November 26, 2008
Last updated: October 7, 2015
Last verified: July 2015

November 26, 2008
October 7, 2015
November 2009
July 2014   (final data collection date for primary outcome measure)
Each of the 7 trials has its own primary outcome: [ Time Frame: 1 year ] [ Designated as safety issue: No ]

PHYSICAL FUNCTION: Increase from baseline of ≥ 50 m in 6 minute walk test. SEXUAL FUNCTION: Change from baseline in responses to Question 4 of the Harbor-UCLA Sexual Function Questionnaire.

VITALITY: Increase from baseline in score on the FACIT-Fatigue scale by ≥ 4 points.

COGNITIVE FUNCTION: Change from baseline in responses to the Wechsler Memory Scale Revised (WMS-R) Logical Memory II, in men with AAMI at baseline.

CARDIOVASCULAR: Change from baseline in non-calcified plaque volume as measured by CT angiography.

BONE: Percent change from baseline in volumetric bone mineral density of trabecular bone of the spine as measured by quantitative computed tomography (QCT) scan.

ANEMIA: Increase in hemoglobin by ≥ 1.0 g/dL in men with anemia of unknown cause at baseline.

To test the hypothesis that testosterone treatment for one year compared to placebo will be associated with improved walking speed, improvement in sexual activity, improvement on the vitality scale and verbal memory test, and anemia correction. [ Time Frame: One year. ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00799617 on Archive Site
The 7 trials have secondary outcomes: [ Time Frame: 1 year ] [ Designated as safety issue: No ]

PHYSICAL FUNCTION: Improvement of ≥ 8 on PF-10/SF-36; change in 6-minute walk distance; both outcomes combined.

SEXUAL FUNCTION: Change Harbor UCLA 7-day Sexual Function Questionnaire, DISF-II-M, IIEF.

VITALITY: Change on the Vitality Scale/SF-36, PANAS, PHQ-9. COGNITIVE FUNCTION: Change on BVRT, Card Rotations, Trails A minus the log-transformed total time for Trails B, 3MSE.

CARDIOVASCULAR: Change measured by CT in log-transformed coronary artery calcium, total plaque volume and subcutaneous fat; change in HgA1C in men not being treated for diabetes; change in HOMA-IR (not limited to those enrolled in cardiovascular trial).

BONE: Change (QCT) in trabecular vBMD, bone strength, cortical bone strength and whole bone strength of the spine; trabecular bone vBMD and whole bone strength of the hip; areal bone mineral density of the spine (DEXA).

ANEMIA: Change from baseline in continuous hemoglobin.

Not Provided
Exploratory Outcomes [ Time Frame: 1 year ] [ Designated as safety issue: No ]
A number of exploratory outcomes have been pre-specified.
Not Provided
The Testosterone Trial in Older Men
Randomized, Placebo-controlled, Double-blind Study of Five Coordinated Testosterone Treatment Trials in Older Men

The Testosterone Trials are a multi-center set of trials involving 12 clinical sites geographically distributed across the United States.

The primary specific aims are to test the hypotheses that testosterone treatment of elderly men whose serum testosterone concentrations are unequivocally low - and who have symptoms and objectively measured abnormalities in at least one of five areas that could be due to low testosterone (physical or sexual function, vitality, cognition, and anemia) - will result in more favorable changes in those abnormalities than placebo treatment.

Two additional trials have been incorporated into the T Trial. Only men enrolled in the T Trial are eligible to participate in these trials.

  • The Cardiovascular Trial will examine if testosterone treatment results in more favorable changes in cardiovascular risk factors, compared to placebo.
  • The Bone Trial will test the hypothesis that testosterone treatment will increase volumetric trabecular bone mineral density (vBMD) of the lumbar spine as measured by quantitative computed tomography (QCT), compared with placebo treatment.

A Pharmacokinetic (PK) Study is also being conducted within the context of the interventional T Trial. It will examine the variability of the serum testosterone (T) concentration after application of testosterone gel or placebo, four months after the start of treatment.

As men get older, they experience many conditions, often together, that eventually result in the inability to perform many activities of daily living, an increased propensity to fall, and decreased independence. These conditions include mobility disability and low vitality. Elderly men also experience increased anemia, metabolic syndrome, decreased sexual function and memory impairment. These conditions likely have multiple causes, but one cause that could contribute to all of them is a low serum testosterone concentration. When young hypogonadal men are treated with testosterone, they experience improvements in sexual function, muscle mass and strength, bone mineral density, sense of well being, and anemia. However, the benefits of testosterone therapy in older men with age-related decline in testosterone concentration are not known and are the subject of this investigation.

Participants will be treated with testosterone or placebo gel for 1 year. The dose will be adjusted in a blinded fashion to achieve a target T level range. Participants will be followed for one additional year following the treatment phase to assess adverse events.

  • Men participating in the Cardiovascular Trial will be assessed for changes in atherosclerotic plaque burden from 0 to 12 months.
  • Men participating in the Bone Trial will be assessed by QCT of the spine and hip, DXA of the spine and hip and clinical fractures at 0 and 12 months.
  • Men participating in the PK Study will attend 3 additional study visits for blood draws at the time of the 4-month assessment.
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Drug: AndroGel® (testosterone gel)
Testosterone levels will be measured at regular intervals in order to achieve a testosterone level in the desired range.
Other Name: Testosterone gel
  • Active Comparator: AndroGel® (testosterone gel)
    AndroGel is applied to the shoulders, abdomen or upper arms once a day. Subjects will be instructed to wash their hands after application and not to have contact with women or children while the gel is wet. They will also be asked not to bathe or get this area wet for five hours after application. The initial dose of AndroGel will be 5.0 g (containing 50 mg of testosterone) once a day.
    Intervention: Drug: AndroGel® (testosterone gel)
  • Placebo Comparator: Placebo gel
    Placebo gel is identical to the testosterone gel and is supplied in an identical pump bottle container. It is applied to the shoulders, abdomen or upper arms once a day. Subjects will be instructed to follow the same precautions to avoid contact with others.
    Intervention: Drug: AndroGel® (testosterone gel)

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Active, not recruiting
June 2016
July 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Men greater than or equal to 65 years old
  • Total serum testosterone concentration < 275 and < 300 ng/dL at 7 -10 AM at each of two screening visits

Exclusion Criteria:

  • Diagnosed prostate cancer, prostatic intraepithelial neoplasia (PIN), prostate nodule or, by the Prostate Cancer Risk Calculator, a >35% risk of having overall prostate cancer or >7% risk of having high grade prostate cancer
  • Severe lower urinary tract symptoms (score of > 19) by the International Prostate Symptom Score questionnaire
  • Hemoglobin <10 g/dL or >16.0 g/dL
  • Sleep apnea, diagnosed but untreated
  • Alcohol or substance abuse within the past year (based on self report)
  • Angina not controlled by treatment
  • NYHA class III or IV congestive heart failure
  • Myocardial infarction within the previous 3 months before entry
  • Stroke within the previous 3 months before entry
  • Severe pulmonary disease that precludes physical function tests
  • Serum creatinine >2.2 mg/dL; ALT 3x upper limit of normal; hemoglobin A1c >8.5%, TSH > 7.5mIU/L
  • Diagnosis or treatment for cancer within the past 3 years, with the exception of nonmelanotic skin cancer
  • Body mass index (BMI) >37 kg/m2
  • Mini Mental State Exam (MMSE) Score <24
  • Major psychiatric disorders, including major depression (PHQ-9 score > 14), mania, hypomania, psychosis, schizophrenia or schizoaffective disorders, that are untreated, unstable, have resulted in hospitalization or medication change within the previous three months, or would result in inability to complete the trial efficacy instruments. Subjects whose disorders have been stable while being treated for more than three months are eligible.
  • Use of the following medications within the previous three months:

    • drugs that affect serum testosterone concentration
    • rhGH or megestrol acetate
    • introduction of anti-depressant medication
    • daily use of prednisone for more than two weeks
  • Opiate use within the past three months
  • Skin conditions at the testosterone gel application site, such as ulcer, erosion, lichenification, inflammation, or crust, or generalized skin conditions such as psoriasis or eczema that might affect testosterone absorption or tolerability of the testosterone gel
  • Known skin intolerance to alcohol or allergy to any of the ingredients of testosterone gel

Participants in the T Trial may also enroll in the Cardiovascular and Bone Trials if it is determined that they are eligible based on the specific exclusion criteria.

Participation in the PK Study does not involve additional exclusion criteria.

65 Years and older
Contact information is only displayed when the study is recruiting subjects
United States
U01 AG030644, R01 AG037679
University of Pennsylvania
University of Pennsylvania
  • National Institute on Aging (NIA)
  • National Institute of Neurological Disorders and Stroke (NINDS)
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
  • National Heart, Lung, and Blood Institute (NHLBI)
  • Abbott
Principal Investigator: Peter J Snyder, MD University of Pennsylvania
University of Pennsylvania
July 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP